How Can Metformin Affect Your Kidneys?

Metformin depends almost entirely on your kidneys to leave your body, which makes kidney function the single most important factor in whether the drug works safely or dangerously accumulates. The relationship cuts both ways, though: while poor kidney function raises the risk of metformin building up to toxic levels, a growing body of research suggests metformin may actually protect kidney tissue from damage in people whose kidneys still function well enough to clear it. Understanding how your kidneys handle metformin, and how metformin handles your kidneys, matters whether you are newly prescribed the drug or have been taking it for years.

Your Kidneys Do Nearly All the Work of Clearing Metformin

Unlike most drugs, metformin is not broken down by your liver. It passes through largely unchanged and gets pumped into urine by specialized transporters in the kidney, particularly a protein called organic cation transporter 2 (OCT2). Research has shown that metformin is a far better fit for this kidney transporter than for the similar transporter in the liver, which is why the kidneys dominate metformin elimination.¹ These same transporters also handle other drugs, meaning that certain medications taken alongside metformin can compete for the same pathway and potentially slow its clearance.²

Because the kidneys are doing virtually all the heavy lifting, anything that reduces kidney function, whether it is chronic kidney disease, dehydration, an acute illness, or aging, directly affects how quickly metformin leaves your bloodstream. When clearance slows, metformin levels rise, and at high enough concentrations the drug starts to pose real risks.

The eGFR Thresholds That Determine Safe Use

Doctors gauge kidney function using estimated glomerular filtration rate, or eGFR, a number that reflects how well your kidneys filter waste. For metformin, the thresholds break into three zones:

eGFR at or above 45: Metformin can be used safely at standard doses.
eGFR between 30 and 44: If you are already taking metformin, the daily dose should generally be capped at 1,000 mg. New prescriptions in this range are not recommended.
eGFR below 30: Metformin is contraindicated.

These cutoffs, endorsed by multiple diabetes and nephrology societies, reflect a consensus that the risk of accumulation outweighs the benefit once kidneys are filtering at less than about a third of their normal capacity.³ If you have been told your eGFR is declining, expect your doctor to check it periodically and adjust your metformin dose or switch medications as needed.

The Lactic Acidosis Risk and Why It Is Rarer Than You Think

For decades, the biggest fear around metformin and kidneys was lactic acidosis, a dangerous buildup of lactic acid in the blood. The concern is real but often overstated. Metformin-associated lactic acidosis (MALA) typically requires two things happening at once: elevated metformin levels (from impaired kidney function) and a second event that disrupts how your body produces or clears lactate, such as severe infection, liver disease, or a major drop in blood flow.⁴

In practice, MALA is extremely uncommon when metformin is prescribed within the recommended eGFR limits. The cases that make it into medical literature almost always involve people who either had unrecognized kidney failure, took far more than their prescribed dose, or were hit by an acute illness that suddenly shut their kidneys down while metformin was still on board. This is why doctors emphasize temporarily stopping metformin before procedures involving contrast dye or during any hospitalization where kidney function could rapidly change.

A Shifting Reputation

Metformin was traditionally treated as flatly contraindicated in chronic kidney disease. If you had any significant decline in kidney function, you were told to stop taking it. Over the past decade or so, guidelines have loosened considerably, now permitting therapy in many patients with moderate kidney disease as long as eGFR stays above 30.⁵ That shift happened because accumulating evidence suggested the old rules were leaving effective treatment on the table. A systematic review covering studies in people with chronic kidney disease found that those taking metformin had a roughly 22% lower chance of dying during follow-up compared to those not taking it.⁶ That kind of mortality benefit is hard to ignore, especially for a cheap, well-studied drug.

The practical result is that if you have mild-to-moderate kidney disease and diabetes, your doctor today is far more likely to keep you on metformin than they would have been fifteen years ago, just with closer monitoring and possible dose reductions.

How Metformin May Actually Protect Kidney Tissue

The most surprising part of the metformin-kidney story is that the drug appears to shield kidney cells from several forms of damage, at least in laboratory and animal studies. The protective effects seem to work through multiple pathways at once.

In diabetic animal models, metformin reduced oxidative damage and fibrosis (the scarring process that gradually destroys kidney tissue) while also dialing down inflammatory signals like TNF-α and IL-1β. Researchers traced much of this to metformin’s activation of an energy-sensing pathway called AMPK, which triggers a cellular cleanup process known as autophagy. Think of it as metformin flipping on the kidney cell’s internal recycling system, clearing out damaged components before they cause further harm.⁷ Separate research in diabetic rats confirmed similar findings: metformin eased oxidative stress, enhanced autophagy, and slowed abnormal cell growth in kidney tissue.⁸

The anti-fibrotic angle is particularly interesting because fibrosis is one of the main ways chronic kidney disease progresses. Animal studies have shown metformin can blunt the scarring process by suppressing a signaling chain that drives excessive tissue remodeling.⁹ There is also evidence that metformin protects podocytes, specialized cells in the kidney’s filtering units that are critical for keeping protein out of your urine. When podocytes are lost, kidney filtration deteriorates.¹⁰

Beyond diabetic kidney disease, metformin has shown protective effects in models of kidney injury from reduced blood flow (ischemia-reperfusion injury), the kind of damage that can happen during surgery or severe episodes of low blood pressure. Again, the autophagy-boosting mechanism through AMPK appeared to be the key driver, with treated animals showing better kidney function tests and less tissue damage.¹¹

A big caveat: most of this evidence comes from animal and cell studies. The findings are consistent and encouraging, but translating them into definitive human treatment guidelines takes longer and larger clinical trials. Still, the direction of evidence helps explain why the medical community became more comfortable keeping patients with mild kidney impairment on metformin.

Adding an SGLT2 Inhibitor to the Mix

SGLT2 inhibitors (drugs like empagliflozin and dapagliflozin) have become a major force in kidney protection for people with diabetes and chronic kidney disease. When researchers looked at what happens when patients take both metformin and an SGLT2 inhibitor, the combination appeared to outperform an SGLT2 inhibitor alone. A real-world cohort study found that the combination group had about a 35% lower risk of a composite kidney outcome and roughly a 26% lower risk of dying from any cause compared to patients on SGLT2 inhibitors without metformin.¹²

This is observational data, not a randomized trial, so the patients who took both drugs may have differed from those who did not in ways the researchers could not fully adjust for. But the magnitude of benefit was striking and consistent enough that it feeds into the broader case for metformin’s kidney-friendly profile when used appropriately.

What Happens in a Metformin Overdose

Because metformin relies on the kidneys for clearance, an overdose, whether intentional or accidental, can escalate quickly, especially if kidney function is already compromised. When metformin builds up to dangerously high levels, hemodialysis becomes the primary rescue tool. The drug is water-soluble and not bound to blood proteins, which makes dialysis effective at pulling it out of the bloodstream.¹³

However, metformin also distributes into tissues, so a short dialysis session may not be enough. In one well-documented case, an initial 3.5-hour session did not meaningfully improve the patient’s condition. It took an additional 31 hours of continuous dialysis before lactate levels came down and clinical status improved. Even after roughly 25 hours of that extended session, blood metformin levels were still about five times the upper therapeutic limit.¹⁴ The takeaway for emergency medicine: severe metformin toxicity can require prolonged, sometimes marathon-length dialysis, particularly if the patient’s own kidneys are not helping clear the drug.

Polycystic Kidney Disease and an Unexpected Research Frontier

One of the more intriguing areas of metformin research has nothing to do with diabetes at all. Autosomal dominant polycystic kidney disease (ADPKD) is a genetic condition where fluid-filled cysts grow in the kidneys, gradually replacing functional tissue and often leading to kidney failure. The only approved treatment, tolvaptan, comes with significant side effects and monitoring requirements, so researchers have been looking for alternatives.

In a mouse model of slowly progressive ADPKD, metformin reduced kidney size relative to body weight and lowered the cystic index compared to untreated controls.¹⁵ A small human feasibility trial then tested metformin against placebo in ADPKD patients. Overall, the differences in kidney growth and function decline did not reach statistical significance, but the numbers leaned in metformin’s favor. Notably, in a subgroup of patients with larger kidneys (those with more advanced disease), kidney growth was significantly slower in the metformin group.¹⁶ The trial was small and designed mainly to check safety and feasibility, so no one is claiming metformin is a proven ADPKD treatment. But the signal was strong enough that larger trials are worth pursuing.

Kidney Stones and Metformin

Calcium oxalate kidney stones are common in people with diabetes, and there is emerging evidence that metformin may interfere with the stone-forming process. In laboratory and animal experiments, metformin inhibited the formation of calcium oxalate crystals and promoted a shift toward a less stable crystal form that is easier for the body to flush out. It also reduced oxidative injury to the cells lining the kidney tubules, the very cells where crystals tend to stick, and decreased crystal deposits in rat kidneys.¹⁷ If these findings translate to humans, metformin could carry a secondary benefit for stone-prone patients, though clinical trials specifically testing this are still needed.

Metformin and Kidney Cancer Survival

A separate line of research has examined whether metformin affects outcomes in people who already have kidney cancer. A meta-analysis pooling data from multiple studies found that metformin use was associated with meaningfully improved survival in kidney cancer patients with diabetes. Overall survival improved by roughly a third, and the benefit appeared strongest in patients with localized renal cell carcinoma, where cancer-specific survival was substantially better in metformin users.¹⁸ These are observational findings, and the people taking metformin may have differed from non-users in unmeasured ways. But the consistency across studies has made metformin an active area of oncology research.

Vitamin B12 Deficiency and Its Kidney Connection

Long-term metformin use is well established to lower vitamin B12 levels, and this side effect has a roundabout connection to kidney health. Prolonged B12 deficiency can cause peripheral neuropathy, the same nerve damage that diabetes itself causes, making it easy to miss or misattribute. It can also lead to a type of anemia where red blood cells grow abnormally large.¹⁶ For people with chronic kidney disease, who are already prone to anemia from reduced production of erythropoietin, adding B12-related anemia on top can complicate diagnosis and management. The practical step is straightforward: if you have been on metformin for several years, ask your doctor to check your B12 level periodically, especially if you have any tingling, numbness, or unexplained fatigue.

Evidence across multiple observational studies and meta-analyses has confirmed the link between long-term, higher-dose metformin use and B12 depletion.¹⁶ This is not a reason to stop metformin, but it is a reason to monitor and supplement when needed.

Situations Where You Should Temporarily Pause Metformin

Even with healthy kidneys, there are moments when metformin should be briefly stopped to avoid accumulation during a sudden dip in kidney function. The classic scenarios include:

Contrast dye procedures: CT scans and certain cardiac procedures use iodinated contrast agents that can temporarily reduce kidney function. Most guidelines recommend stopping metformin on the day of the procedure and restarting once kidney function has been confirmed stable, usually 48 hours later.
Acute illness with dehydration: Vomiting, diarrhea, or high fevers can reduce blood flow to the kidneys rapidly. Holding metformin during these episodes and restarting when you are hydrated and eating normally is standard advice.
Major surgery: Anesthesia and surgical stress can transiently impair kidney perfusion. Surgeons and anesthesiologists will typically instruct you to stop metformin before an operation.
Heavy alcohol intake: Alcohol impairs your liver’s ability to clear lactate, which compounds the lactic acidosis risk if metformin levels are elevated.

None of these situations mean metformin is dangerous in general. They mean that the drug’s reliance on kidney clearance requires a bit of situational awareness. Once the acute event passes and kidney function is back to baseline, metformin can almost always be resumed.